Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Johnson and Johnson
Harvard Business School
Colorcon
Boehringer Ingelheim

Last Updated: June 27, 2022

CLINICAL TRIALS PROFILE FOR SELPERCATINIB


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Selpercatinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03155620 ↗ Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting National Cancer Institute (NCI) Phase 2 2017-07-24 This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
NCT03157128 ↗ A Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer Recruiting Eli Lilly and Company Phase 1/Phase 2 2017-05-02 This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
NCT03157128 ↗ A Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer Recruiting Loxo Oncology, Inc. Phase 1/Phase 2 2017-05-02 This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
NCT03899792 ↗ A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors Recruiting Eli Lilly and Company Phase 1/Phase 2 2019-06-13 This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Selpercatinib

Condition Name

Condition Name for Selpercatinib
Intervention Trials
Healthy 8
Medullary Thyroid Cancer 4
Non-Small Cell Lung Cancer 3
Refractory Osteosarcoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Selpercatinib
Intervention Trials
Carcinoma, Non-Small-Cell Lung 6
Thyroid Neoplasms 5
Thyroid Diseases 5
Lung Neoplasms 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Selpercatinib

Trials by Country

Trials by Country for Selpercatinib
Location Trials
United States 226
China 62
Japan 41
Korea, Republic of 23
Spain 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Selpercatinib
Location Trials
Texas 11
Florida 10
California 10
Massachusetts 9
New York 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Selpercatinib

Clinical Trial Phase

Clinical Trial Phase for Selpercatinib
Clinical Trial Phase Trials
Phase 3 3
Phase 2 7
Phase 1/Phase 2 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Selpercatinib
Clinical Trial Phase Trials
Recruiting 10
Completed 5
Not yet recruiting 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Selpercatinib

Sponsor Name

Sponsor Name for Selpercatinib
Sponsor Trials
Eli Lilly and Company 19
Loxo Oncology, Inc. 14
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Selpercatinib
Sponsor Trials
Industry 34
Other 9
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Colorcon
McKesson
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.